tetano
Editor, Senior Moderator
J Infect Dis
. 2023 Nov 14:jiad496.
doi: 10.1093/infdis/jiad496. Online ahead of print. The SARS-CoV-2 infection in the pediatric oncology population: the definitive comprehensive report of Infectious Diseases Working Group (IDWG) of AIEOP
Daniele Zama[SUP] 1 [/SUP], Andrea Zanaroli[SUP] 2 [/SUP], Agnese Corbelli[SUP] 3 [/SUP], Andrea Lo Vecchio[SUP] 4 [/SUP], Margherita Del Bene[SUP] 4 [/SUP], Antonella Colombini[SUP] 5 [/SUP], Francesca Compagno[SUP] 6 [/SUP], Angelica Barone[SUP] 7 [/SUP], Ilaria Fontanili[SUP] 7 [/SUP], Maria Rosaria D'Amico[SUP] 8 [/SUP], Maria Rosaria Papa[SUP] 8 [/SUP], Maria Grazia Petris[SUP] 9 [/SUP], Elisabetta Calore[SUP] 10 11 [/SUP], Shana Montalto[SUP] 12 [/SUP], Linda Meneghello[SUP] 13 [/SUP], Letizia Brescia[SUP] 14 [/SUP], Rosamaria Mura[SUP] 15 [/SUP], Milena La Spina[SUP] 16 [/SUP], Paola Muggeo[SUP] 17 [/SUP], Simona Rinieri[SUP] 18 [/SUP], Cristina Meazza[SUP] 19 [/SUP], Katia Perruccio[SUP] 20 [/SUP], Monica Cellini[SUP] 21 [/SUP], Manuela Spadea[SUP] 22 23 [/SUP], Federico Mercolini[SUP] 2 24 [/SUP], Valeria Petroni[SUP] 25 [/SUP], Raffaella De Santis[SUP] 26 [/SUP], Elena Soncini[SUP] 27 [/SUP], Massimo Provenzi[SUP] 28 [/SUP], Nagua Giurici[SUP] 29 [/SUP], Ottavio Ziino[SUP] 30 [/SUP], Gloria Tridello[SUP] 3 [/SUP], Simone Cesaro[SUP] 3 [/SUP]
Affiliations
Objective: The objective of this study was to assess the clinical impact and outcome of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection on children with cancer or who received a hematopoietic stem cell transplantation (HSCT).
Study design: The Italian Association of Pediatric Hematology and Oncology (AIEOP) performed a nationwide, multicenter, observational cohort study, including consecutive patients between April 2020 to November 2022.
Results: Twenty-five Italian centers participated and 455 patients were enrolled. We reported a significative increasing trend of symptomatic cases over the years, while the number of non-mild infections remained stable. An early infection after the oncological diagnosis (<60 days) and severe neutropenia have been identified as independent risk factors for developing moderate, severe or critical infections. The percentage of asymptomatic and mildly symptomatic patients who stopped chemotherapy reduced over the years of the pandemic. Nine patients died, but no death was attributed to SARS-CoV-2 infection.
Conclusions: SARS-CoV-2 infection presented a self-limiting, benign course in the Italian pediatric onco-hematology population during the pandemic and its main consequence has been the discontinuation of cancer-directed therapies. The rate of asymptomatic patients who stopped chemotherapy reduced over the years, suggesting that the continuation of chemotherapy is a feasible option.
Keywords: Chemotherapy; Hematopoietic Stem Cell Transplantation; Pediatric Hematology; Pediatric Oncology; SARS-CoV-2.
. 2023 Nov 14:jiad496.
doi: 10.1093/infdis/jiad496. Online ahead of print. The SARS-CoV-2 infection in the pediatric oncology population: the definitive comprehensive report of Infectious Diseases Working Group (IDWG) of AIEOP
Daniele Zama[SUP] 1 [/SUP], Andrea Zanaroli[SUP] 2 [/SUP], Agnese Corbelli[SUP] 3 [/SUP], Andrea Lo Vecchio[SUP] 4 [/SUP], Margherita Del Bene[SUP] 4 [/SUP], Antonella Colombini[SUP] 5 [/SUP], Francesca Compagno[SUP] 6 [/SUP], Angelica Barone[SUP] 7 [/SUP], Ilaria Fontanili[SUP] 7 [/SUP], Maria Rosaria D'Amico[SUP] 8 [/SUP], Maria Rosaria Papa[SUP] 8 [/SUP], Maria Grazia Petris[SUP] 9 [/SUP], Elisabetta Calore[SUP] 10 11 [/SUP], Shana Montalto[SUP] 12 [/SUP], Linda Meneghello[SUP] 13 [/SUP], Letizia Brescia[SUP] 14 [/SUP], Rosamaria Mura[SUP] 15 [/SUP], Milena La Spina[SUP] 16 [/SUP], Paola Muggeo[SUP] 17 [/SUP], Simona Rinieri[SUP] 18 [/SUP], Cristina Meazza[SUP] 19 [/SUP], Katia Perruccio[SUP] 20 [/SUP], Monica Cellini[SUP] 21 [/SUP], Manuela Spadea[SUP] 22 23 [/SUP], Federico Mercolini[SUP] 2 24 [/SUP], Valeria Petroni[SUP] 25 [/SUP], Raffaella De Santis[SUP] 26 [/SUP], Elena Soncini[SUP] 27 [/SUP], Massimo Provenzi[SUP] 28 [/SUP], Nagua Giurici[SUP] 29 [/SUP], Ottavio Ziino[SUP] 30 [/SUP], Gloria Tridello[SUP] 3 [/SUP], Simone Cesaro[SUP] 3 [/SUP]
Affiliations
- PMID: 37962869
- DOI: 10.1093/infdis/jiad496
Objective: The objective of this study was to assess the clinical impact and outcome of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection on children with cancer or who received a hematopoietic stem cell transplantation (HSCT).
Study design: The Italian Association of Pediatric Hematology and Oncology (AIEOP) performed a nationwide, multicenter, observational cohort study, including consecutive patients between April 2020 to November 2022.
Results: Twenty-five Italian centers participated and 455 patients were enrolled. We reported a significative increasing trend of symptomatic cases over the years, while the number of non-mild infections remained stable. An early infection after the oncological diagnosis (<60 days) and severe neutropenia have been identified as independent risk factors for developing moderate, severe or critical infections. The percentage of asymptomatic and mildly symptomatic patients who stopped chemotherapy reduced over the years of the pandemic. Nine patients died, but no death was attributed to SARS-CoV-2 infection.
Conclusions: SARS-CoV-2 infection presented a self-limiting, benign course in the Italian pediatric onco-hematology population during the pandemic and its main consequence has been the discontinuation of cancer-directed therapies. The rate of asymptomatic patients who stopped chemotherapy reduced over the years, suggesting that the continuation of chemotherapy is a feasible option.
Keywords: Chemotherapy; Hematopoietic Stem Cell Transplantation; Pediatric Hematology; Pediatric Oncology; SARS-CoV-2.